Radiology Partners to use iCAD's ProFound AI Suite for breast cancer detection across its network

by John R. Fischer, Senior Reporter | July 24, 2023
Artificial Intelligence Business Affairs Women's Health
ProFound AI Detection
Radiology Partners, the largest radiology practice in the U.S., has announced that it will integrate iCAD’s ProFound AI Suite for breast cancer diagnostics among the more than 3,200 facilities where it performs mammography scans on millions of women annually.

iCAD’s technology is designed to improve breast cancer detection and perform risk assessments. It includes ProFound AI Detection, the first FDA-cleared AI technology for 3D mammography; ProFound AI Density Assessment for simplifying and standardizing breast density evaluations; and ProFound AI Risk, the first commercially available solution worldwide that produces accurate short-term breast cancer risk estimations personalized for each woman, based solely on her mammogram.

The two began discussions in November 2022 about a strategic multiyear commercial agreement, which went into effect on June 27. Announced on July 18, the news sent iCAD's stock up 72%, reported MarketWatch.

“We are working with Radiology Partners to deploy iCAD’s technology via the Radiology Partners Cloud, significantly increasing the potential for adoption across their network of facilities and unleashing the ability to improve mammography screening for millions of women across the country,” said Dana Brown, president and CEO of iCAD, in a statement.

Deploying its technology through the Radiology Partners Cloud will provide iCAD, which is based in New Hampshire, with access to the company’s AI validation platform, clinical expertise, scale, and the thousands of physicians under it, including within 17 of the 20 largest health systems in the U.S.

One of Radiology Partner’s sites, the Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital, in Florida, recently discussed at the European Congress of Radiology meeting in March how ProFound AI increased breast cancer detection by 23%, without raising its false positive rate.

“The body of evidence supporting this technology is already generating interest and demand across our network,” said Dr. Nina Kottler, Radiology Partners Associate CMO for clinical artificial intelligence.

Radiology Partners made an initial order for iCAD’s Breast AI Suite in Q1 2023.

You Must Be Logged In To Post A Comment